The Danish Medicines Agency (Lægemiddelstyrelsen) has introduced new restrictions on the dispensing of the diabetes medication Ozempic at Danish pharmacies. Starting next month, citizens will no longer be able to receive more than one year’s supply of the medication at a time. This new rule is part of a broader regulation that will take effect after a consultation period and may also apply to other reimbursable medications. The purpose of the restrictions is to prevent fraud and illegal resale of medication, including Ozempic, which has become a popular target for such activities.
According to the Danish Medicines Agency, pharmacies will also have the right to refuse dispensing more than one year’s supply of all types of reimbursable medication. This measure is being implemented to ensure a more controlled distribution of medication and to protect public health. These new regulations come in response to reports of increased resale of medication, which not only poses a risk of misuse but can also lead to shortages of essential medications for patients in need.
It is important for patients and their relatives to be aware of these changes and to plan their medication purchases accordingly. The Danish Medicines Agency encourages everyone to follow the new guidelines and collaborate with pharmacy staff to ensure a smooth transition to the new regulations.